## Subject index of volume 23

ACNU 301 Actinomycin D 31 Adenomatous hyperplasia S 110 Adriamycin 145, 363, S 17, S 21, S 29 Adriamycin-lipiodol suspension 238 Adult 384, 401 Advanced liver cancer S 9 Alcohol drinking S 114 Allopurinol 169 AMSA 26 Anthracycline 316 Anthracycline cardiotoxicity 401 Anthrapyrazole 8 Anticancer therapy S 4 Antifolate drugs 308 Antineoplastic activity 26 Antineoplastic agents 197 Anti-peplomycin IgE antibody 333 Antitumor activity 15, 219, 337, 341 Arabinoside 373 Ara-C 87 Armoatose inhibitor 47 Arterial chemoembolization S 65 Arterial chemotherapy S 37

Benzo(a)phenazine 135 Biliary excretion 156 Biosynthesis 348 Bladder tumor 181 Bleomycin 333, 358 Bone marrow purging 129 Bone marrow support 377 Breast cancer 68 Buthionine 291

Caerulein S 59 Calmodulin antagonist 358 Cancer trends, Singapore S 13 Carboplatin 181, 243, 323, 331, 367 -, oral 126 Cardiac toxicity 81 CDDP S 42 **CDDP** 219 Cell-killing activity 279 Cervical uterine cancer 333 CGP 6809 266, 337, 341 Chemoembolization S 26, S 42, S 126 - of hepatic artery S 17 Chemotherapy 63, 105, 135, 308, 319, 384, 395, S 49 -, intraarterial 238 Children 392 Chlorambucil 208 CI-921 291 Cigarette smoking S 114 Cimetidine 291 Cisplatin 57, 129, 243, 252, 255, 377, 389, S 126 -, high-dose 276 Clonal growth S1 Colorectal adenocarcinoma 54 Colorectal carcinoma 61 Combination chemotherapy 57, 101

Combination chemotherapy S 9

Cyanomorpholinyl adriamycin 71

Creatinine assay 119

Cyclophosphamide 101, 377
Cyclosporin A 296
Cytosine, high-dose 373
Cytotoxic hexitols 41
Cytotoxicity 87

Dapsone/N-acetylation interaction 395 Daunorubicin 296 DDTC 276 Deoxycoformycin 173 Dermatotoxicity 71 DHBA 1 cis-Diamminedichloroplatinum 37 Dimethylsulfoxide 316 DMBA-induced tumor 47 DNA S1 DNA breaks 161 DNA repair 252 Dominance of resistance 41 Dose escalation 8 Doxorubicin 81, 140, 161 Drug resistance 19, 140 Drug stability in vitro 197

Early gastric cancer 319
Emesis 389
Endotoxin 231
Epirubicin 269
Epirubicin and mitomycin C 51
Etoposide 263, 367, 373

FAM S 9
Fanconi syndrome 121
FCE 24304 47
Feasibility study 331
Flavone acetiv acid 397
Flow cytometry 296
5-Fluorouracil 57, 61, 101, 169, S 9, S 21, S 29, S 121
Folinic acid 353

Gallbladder infarction S 59
Gastric cancer, early 319
Gastric stump 363
Gastrointestinal tract 225
GI tract tumor 192
GR 38032F 389
Growth pattern 319

Hematologic toxicity 323 Hepatectomy S 87 Hepatic arterial chemotherapy S 68 Hepatic artery chemoembolization S 118 Hepatic artery infusion S 121 Hepatic artery ligation 169 Hepatic carcinoma S 59 Hepatic malignancy S 49 Hepatic resection S 78, S 83 Hepatic tumor S 65 Hepatocellular carcinoma S 4, S 13, S 17, \$ 21, \$ 26, \$ 29, \$ 33, \$ 37, \$ 42, \$ 45, S 54, S 78, S 83, S 87, S 101, S 110, S 123 Hepatocyte S1 Hepatoma S 54, S 118, S 126, S 129 High-dose busulfan 87

Homoharringtonine 145
HPLC 208
HT<sub>3</sub> receptor antagonist 389
Human leukemic cells 117
Human melanoma 1
Human tumor necrosis factor 231
Human tumor spheroids 111
Hydrolysis 76
4-Hydroperoxycyclophosphamide 129
Hydroxyurea 26, 252
Hypersensitivity 173
Hyperthermia S 118

ICRF-187 269
Ifosfamide 121, 128, 192, 263, 329
Infusion
-, continuous 192
-, hepatic artery S 121
-, high-dose 252
Infusion chemotherapy S 121
Interferons S 13
Interleukin 2 S 45
Interventional radiology S 54
Iproplatin 61
Irradiation S 13

Kidney 31 Kinetic analysis 279

L1210 cells 19 Leptomeningeal neoplasia 301 Leucovorin 353 Leukaemia 373, 392 -, acute lymphoblastic 384 -, myeloblastic 401 -, myelocytic 26 Linearity 95 Lipiodol S 21, S 90, S 126 Liposome 81, 151, 219 Liver cancer S 104 --, primary S 114 Liver cirrhosis S 78 Liver obstruction 194 Liver resection S 74, S 90 Liver tumor 169 Lung cancer 255 LY186641 119 Lymphoblastic cells 283 Lymphokine-activated killer cells S 45

Major hepatic resection S 101 Malignancy of hepatocellular carcinoma S 96 Malignant tumours 348 Mammary tumors 47 Melphalan 76, 95, 377 Mesna 192, 329 Metabolism 156 Metastatic liver cancer S 68 Methotrexate 101, 156, 259, 263 Mitomycin C 115, S 9, S 121 Mitoxantrone 54, 140 Multidrug resistance 161 Multimodal treatment S 87 Multiple myeloma 76 Murine leukemia 145 Murine tumors 135, 140 Myeolocytic leukemia 26

Nausea 389 Navelbine 247 Neocarzinostatin 279 Neurotoxicity 71 Nitrosourea 266 Non-Hodgkin's lymphoma 123, 263 Non-small-cell lung cancer 111

OK 432 S 9 Ovarian cancer 51, 105, 323, 331 Oxantrazole 213

P388 145 Pain S 65 Peplomycin 333 Pharmacokinetics 8, 126, 156, 176, 243, 247, 311, 367, 392 -, comparative 208 Pharmacological properties 341 Pharmacology 397 Phase I trial 348, 358 Plasma 353 Platinum analogues 111 Platinum complexes 15 Platinum kinetics 37 P388 leukemia cells 296 P388 lymphoma 41 Portal hypertension S 78 Predinimustine 105, 208 Prednisolone 392 Prognosis S 96, S 123, S 129 Prophylaxis 389

Prostatic carcinoma 115
Protein binding 76
Protein binding 397
Pteridine transport 283
PTT-119 123
Putrescine 348

Radiation effects 117
Radioiodinated fatty acid ester S 54, S 118
Radiotherapy S 49
Rat leukemia 26
Renal elimination 156
Renal function 255, 329
Retinoblastoma 63

Sarcomatous appearance S 4
Sodium thiosulfate 255
Solid tumors 186, 259
Sorcin 19
Squamous cell carcinoma 128
Synergism 129

Tamoxifen 194
Targeting chemotherapy S 17
Targetted treatment S 13
Tauromustine 176
Teniposide 161
Test dose 95
Testicular teratoma 367

Testicular tumor 181 Tetrahydrofolates 353 Therapeutic chemoembolization S 123 THP-adriamycin 311 Tissue damage 316 Titanocene complexes 225 TNF 231 Toxicity 8, 219, 231, 259 -, renal 269 Transcatheter arterial chemoembolization S 21, S 29, S 33,m S 37, S 49, S 59, Transplantation S 104 Treatment strategies S 13 Trifluoperazine 358 Tumor growth rate S 96 Tumor necrosis factor 186 Tumor tamoxifen 68

Valinomycin 151 Venous administration 363 Viability 145 Vinca alkaloid 247 Vincristine 31

Water jet S 74 Wilms' tumor 31

Xenografted human adenocarcinoma 225 Xenografts 337

